Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges

Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges

Frontline treatment for classical Hodgkin lymphoma is undergoing one of the most significant transformations in modern hematology. Following the SWOG S1826 trial and FDA approval of nivolumab-based frontline therapy in 2026, clinicians are rapidly adopting immunotherapy-forward regimens that improve disease control while reducing long-term toxicity. Emerging PET-adapted strategies, response-guided de-escalation, and novel combinations involving PD-1 blockade and CD30-directed therapy are reshaping how oncologists balance cure rates, survivorship, and quality of life for patients with Hodgkin lymphoma.

INTRODUCTION / CONTEXT: The Evolution of Frontline Therapy in Classical Hodgkin Lymphoma

Classical Hodgkin lymphoma (cHL) is one of the most curable cancers in oncology, yet the field has long grappled with a fundamental tension: delivering enough treatment to cure the disease while minimizing the long-term toxicities that can haunt survivors for decades. For years, the ABVD regimen and its derivatives dominated the frontline landscape. That paradigm has now shifted decisively.

The SWOG S1826 trial, presented at ASCO 2023, introduced compelling phase 3 data supporting a nivolumab-containing frontline regimen for advanced-stage cHL, triggering one of the most dramatic market shifts seen in a hematologic malignancy in recent memory. FDA approval for Nivolumab AVD in advanced-stage disease in March 2026 — the frontline treatment landscape for Hodgkin lymphoma had been fundamentally redrawn. Understanding what drove this shift, and what it means for patients and clinicians, is essential.

EXPERT ANALYSIS / INTERPRETATION: Why PD-1 Blockade Has Become Central in Hodgkin Lymphoma

Prior to 2023, brentuximab vedotin plus AVD (A+AVD) held an estimated 95% market share in frontline advanced Hodgkin lymphoma in the United States, driven by the Echelon-1 trial data demonstrating improved modified progression-free survival versus ABVD. The subsequent rapid erosion of that dominance — down to roughly 5% by early 2026 — reflects the strength of the SWOG S1826 trial data and the oncology community's appetite for chemotherapy-sparing, immunotherapy-forward regimens.

The scientific rationale for incorporating PD-1 blockade into frontline Hodgkin's therapy is well established. Reed-Sternberg cells exploit the PD-1/PD-L1 axis to evade immune surveillance, and PD-1 inhibitors have demonstrated single-agent response rates exceeding 80% in relapsed/refractory cHL. The addition of Nivolumab to AVD chemotherapy backbone , appears to deliver superior disease control with a more favorable toxicity profile compared to brentuximab AVD conventional approaches.

An important practical consideration accompanying the new regimen is the FDA's recommendation for routine growth factor prophylaxis. This guidance stems from lessons learned during Echelon-1, where the absence of growth factor support was associated with neutropenic fever rates approaching 35% — substantially higher than typically seen with standard ABVD. Prophylactic granulocyte colony-stimulating factor (G-CSF) administration has since become a standard component of A+AVD delivery; the same principle applies to the evolving brentuximab/nivolumab-containing regimens, where myelosuppression remains a meaningful clinical concern.

The German BrECAD regimen warrants specific discussion, as it represents an alternative approach frequently cited in the global literature.BrECADD and its predecessors from the German Hodgkin Study Group have consistently achieved excellent disease control rates. However, these regimens exact a substantial toxicity toll — including transfusion requirements (blood and platelets) in 25 to 30% of patients, far exceeding what is observed with contemporary American regimens. For a disease that predominantly affects teenagers and young adults, this level of treatment-related morbidity is difficult to justify, particularly when comparable cure rates can be achieved with less toxic approaches. Critically, patients treated in the United States health care context often cannot afford to stop working during treatment — their ability to maintain employment and health insurance during therapy is not merely a marker of a more tolerable regimen; it is a practical necessity of their circumstances.

The concept of response-adapted de-escalation also merits emphasis. With modern PET-adapted strategies, patients who achieve PET negativity after cycles 2 and 4 may not require the traditional 6 cycles of therapy. Ongoing cycles 5 and 6 in PET-negative patients reflect historical tradition rather than prospective evidence of benefit. Tailoring treatment duration to individual response — with rigorous PET imaging — represents an important opportunity to reduce cumulative toxicity without compromising cure rates.

Similarly, the role of consolidative radiation therapy deserves careful scrutiny. Hodgkin lymphoma is exquisitely radiosensitive, and radiation remains a powerful tool in selected cases. However, the late effects of mediastinal radiation — including secondary malignancies, cardiac disease, and pulmonary fibrosis — manifest decades after treatment in patients who are otherwise long-term survivors. Radiation decisions made today will shape the health of 18-year-olds well into their forties and beyond. That long-term lens must inform every discussion about consolidative radiotherapy.

The Combination Strategy: Growth Factor Prophylaxis and Toxicity Management

Early Stage Hodgkin Lymphoma

The rationale for combining brentuximab vedotin with PD-1 inhibition and chemotherapy lies in the complementary mechanisms of CD30-directed cytotoxicity and immune checkpoint blockade, enabling both direct tumor cell killing and immune-mediated tumor clearance. The SGN35-027 Part C study was a phase 2, open-label, multicenter trial evaluating four cycles of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) in patients with early-stage nonbulky classical Hodgkin lymphoma. The primary endpoint was complete response at end of treatment, which was achieved in approximately 92% of patients, with an estimated 2-year progression-free survival of 97%, notably without the routine use of consolidative radiation . The regimen demonstrated a favorable safety profile, with no febrile neutropenia and manageable immune-related toxicities, including pneumonitis and thyroid dysfunction; however, peripheral neuropathy remained a relevant adverse event, occurring in nearly half of patients, predominantly grade 1–2. These findings suggest that immunotherapy-based, chemotherapy-light approaches can reproduce outcomes historically achieved with combined modality therapy, including radiation, consistent with signals observed in the NIVAHL experience. From a conceptual standpoint, this study challenges the necessity of fixed treatment duration, raising the possibility that four cycles may represent overtreatment in a subset of patients. As circulating tumor DNA (ctDNA) and functional imaging continue to mature, further refinement toward response-adapted de-escalation appears both feasible and necessary.

Advanced Stage Hodgkin Lymphoma

The rationale for omitting vinblastine and incorporating nivolumab while maintaining brentuximab vedotin is to reduce overlapping microtubule-associated toxicity while enhancing immune-mediated antitumor activity. The SGN35-027 Part B study was a phase 2, open-label, multicenter trial conducted in advanced-stage disease, evaluating up to six cycles of AN+AD with endpoints including complete response and progression-free survival. The study demonstrated a complete response rate of 88% and an estimated 2-year progression-free survival of approximately 88%, confirming meaningful clinical activity in this population . The safety profile was notable for the absence of febrile neutropenia and lower rates of severe myelosuppression compared with historical vinblastine-containing regimens, although peripheral neuropathy was observed in approximately 44% of patients, largely low grade, and immune-mediated adverse events such as hypothyroidism and pneumonitis were manageable. These results support the hypothesis that removal of vinblastine may mitigate hematologic toxicity while preserving efficacy through immunologic synergy. However, when viewed in the context of contemporary benchmarks such as SWOG S1826, the progression-free survival, while favorable, does not clearly exceed existing standards. This raises an important strategic question for the field: although synergy is evident and toxicity is improved, can we further optimize this backbone by refining agent selection, sequencing, or duration to achieve superior outcomes?

The combination of PD-1 blockade with a CD30-directed antibody-drug conjugate represents a foundational strategy in modern Hodgkin lymphoma therapy; the remaining question is not feasibility, but optimal intensity. The investigator-initiated study of pembrolizumab in combination with brentuximab vedotin plus doxorubicin and dacarbazine employed a PET-adapted design, allowing treatment duration to be individualized based on early metabolic response and reduction in total metabolic tumor volume. The phase 2 study, presented at ASH 2025, demonstrated a complete response rate of approximately 88% and an early progression-free survival approaching 96% at a median follow-up of ~15 months, supporting strong frontline activity. The safety profile was favorable, with low rates of neutropenic fever and predictable, manageable immune-related toxicities, while peripheral neuropathy appeared reduced relative to vinblastine-containing regimens. Importantly, all patients achieving early complete metabolic response were eligible for treatment de-escalation, resulting in a substantial reduction in cumulative anthracycline and alkylator exposure. These findings reinforce the principle that response-adapted, immunotherapy-forward strategies can meaningfully reduce treatment burden without compromising efficacy. The broader implication for the field is a shift toward biologically guided therapy, where depth of response—not historical convention—determines treatment intensity, ultimately challenging the necessity of fixed-duration chemotherapy in Hodgkin lymphoma.

CLINICAL IMPLICATIONS / PRACTICE TAKEAWAYS

• The brentuximab vedotin plus nivolumab-containing regimen has emerged as the new frontline standard for advanced-stage classical Hodgkin lymphoma, supported by SWOG S1826 trial data and FDA approval in March 2026. Majority of clinicians have already made the transition.
• Growth factor prophylaxis (G-CSF) should be routinely incorporated into brentuximab-containing frontline regimens to mitigate the risk of neutropenic fever, which reached 35% in Echelon-1 without prophylaxis.
• BrECADD response-adapted de-escalation is something the USA group have lagged behind— including consideration of stopping/de-escalation of therapy after interim PET-negative patients — is an evidence-supported strategy to reduce cumulative toxicity without sacrificing cure rates.
• Consolidative radiation decisions should be made with explicit consideration of the patient's age, life expectancy, and the long-term risk of radiation-associated toxicities, including secondary malignancies.
• Early-stage Hodgkin lymphoma, while lacking FDA approval for the novel regimen, carries an NCCN recommendation — and the treatment paradigm shift in advanced-stage disease is likely to influence early-stage management discussions going forward.

• Emerging combination strategies incorporating CD30-directed antibody-drug conjugates and PD-1 inhibitors with chemotherapy backbones continue to be actively investigated and are expected to further refine the balance between efficacy and toxicity, shaping the future direction of frontline Hodgkin lymphoma therapy.

PATIENT PERSPECTIVE / PLAIN-LANGUAGE SUMMARY

FOR PATIENTS & FAMILIES

Hodgkin lymphoma is a highly treatable blood cancer, but for many years, the treatments used to cure it came with serious long-term side effects. Now, newer treatments that combine targeted drugs with immunotherapy are showing excellent results — with less chemotherapy and fewer toxic effects. One of these newer approaches was recently approved by the FDA for advanced-stage Hodgkin lymphoma in early 2026. For patients, this means there is now a frontline option that is not only highly effective but designed to protect long-term health. Doctors are also learning that in some patients, treatment can be safely shortened when imaging scans show an excellent early response — sparing patients from additional cycles of therapy they may not need.

KEY TAKEAWAYS

• The SWOG S1826 trial has established a new frontline standard for advanced-stage classical Hodgkin lymphoma, combining chemotherapy backbone with PD-1 blockade, with FDA approval granted in March 2026.
• Routine G-CSF prophylaxis is recommended with brentuximab-containing regimens to prevent high rates of neutropenic fever.
• PET-adapted de-escalation strategies can reduce total treatment cycles in responding patients without compromising cure.
• Consolidative radiation must be weighed against decades-long late effects, particularly in young patients.
• The market shift from A+AVD to novel combinations has been swift and dramatic — reflecting the strength of the clinical evidence.

REFERENCES / LINKS

1. Herrera AF, et al. Nivolumab + brentuximab vedotin ± chemotherapy for advanced-stage classical Hodgkin lymphoma (SWOG S1826 trial). ASCO Plenary Session, 2023.

2. Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma (Echelon-1). N Engl J Med. 2018;378(4):331-344.

3. FDA approval announcement. Brentuximab vedotin combination for advanced-stage classical Hodgkin lymphoma, March 2026.

4. Engert A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial). Lancet. 2012;379(9828):1791-1799.

5. The Cancer News. PET-Adapted Strategies in Hodgkin Lymphoma: Where Are We Now? cancernews.com.

6. Lee HJ, Ravizzini G, Wixom J, et al. Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine: phase 2 study. Blood. 2025;146(suppl 1):153. doi:10.1182/blood-2025-153

7. Lee HJ, Ramchandren R, Friedman J, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025;145(3):290-299. [doi:10.1182/blood.2024025114].